MCA Stability Tool

Medicines under this category are suitable for use in MCAs, although use is likely to be off-label.   Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

There are concerns about stability and/or there is a lack of stability data available. Medicines under this category can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.   Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Medicines under this category are not suitable for use in MCAs.

These medicines have not been reviewed by SPS.